Barclays upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from an equal weight rating to an overweight rating in a research report released on Friday morning, MarketBeat.com reports. They currently have $107.00 target price on the biotechnology company’s stock, up from their prior target price of $55.00.
Several other brokerages have also recently weighed in on SRPT. UBS cut Sarepta Therapeutics from an outperform rating to a market perform rating in a report on Friday, May 4th. BidaskClub raised Sarepta Therapeutics from a buy rating to a strong-buy rating in a report on Friday,....More>>>